Ptc Therapeutics Stock Beneish M Score
| PTCT Stock | USD 25.21 0.20 0.79% |
PTC | Beneish M Score |
At this time, it appears that PTC Therapeutics is an unlikely manipulator. The earnings manipulation may begin if PTC Therapeutics' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by PTC Therapeutics executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of PTC Therapeutics' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-3.09
Beneish M Score - Unlikely Manipulator
PTC Therapeutics Beneish M-Score Indicator Trends
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if PTC Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Net Receivables | 169.1 M | 161 M |
|
| |||||
| Total Revenue | 984.7 M | 937.8 M |
|
| |||||
| Total Assets | 2 B | 1.9 B |
|
| |||||
| Total Current Assets | 1.3 B | 1.2 B |
|
| |||||
| Non Current Assets Total | 480.6 M | 684.6 M |
|
| |||||
| Property Plant Equipment | 87.7 M | 83.5 M |
|
| |||||
| Selling General Administrative | 366.4 M | 349 M |
|
| |||||
| Total Current Liabilities | 633.3 M | 603.1 M |
|
| |||||
| Non Current Liabilities Total | 2.2 B | 2.1 B |
|
| |||||
| Short Term Debt | 15.2 M | 16 M |
|
| |||||
| Short Term Investments | 281.6 M | 282.7 M |
|
|
PTC Therapeutics Beneish M-Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between PTC Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards PTC Therapeutics in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find PTC Therapeutics' degree of accounting gimmicks and manipulations.
Click cells to compare fundamentals
About PTC Therapeutics Beneish M Score
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Depreciation And Amortization |
|
PTC Therapeutics Earnings Manipulation Drivers
Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as PTC Therapeutics. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Receivables | 55.5M | 69.9M | 110.5M | 155.6M | 161.0M | 169.1M | |
| Total Revenue | 307.0M | 380.8M | 538.6M | 698.8M | 937.8M | 984.7M | |
| Total Assets | 1.6B | 2.2B | 1.9B | 1.7B | 1.9B | 2.0B | |
| Total Current Assets | 779.3M | 1.2B | 773.4M | 693.8M | 1.2B | 1.3B | |
| Net Debt | (372.7M) | 211.6M | (341.9M) | 292.9M | (179.0M) | (187.9M) | |
| Short Term Debt | 20M | 8.7M | 159.8M | 12.4M | 16.0M | 15.2M | |
| Long Term Debt | 293.9M | 309.1M | 281.9M | 571.7M | 1.9B | 2.0B | |
| Operating Income | (192.8M) | (397.9M) | (374.9M) | (439.9M) | (349.4M) | (331.9M) | |
| Investments | (341.8M) | (505.6M) | 304.5M | 442.6M | (49.9M) | (47.4M) |
About PTC Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PTC Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PTC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PTC Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as PTC Therapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out PTC Therapeutics Piotroski F Score and PTC Therapeutics Altman Z Score analysis. For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.Note that the PTC Therapeutics information on this page should be used as a complementary analysis to other PTC Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for PTC Stock analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is PTC Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PTC Therapeutics. If investors know PTC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PTC Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.37) | Revenue Per Share 12.531 | Quarterly Revenue Growth 0.834 | Return On Assets (0.12) | Return On Equity (77.40) |
The market value of PTC Therapeutics is measured differently than its book value, which is the value of PTC that is recorded on the company's balance sheet. Investors also form their own opinion of PTC Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is PTC Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PTC Therapeutics' market value can be influenced by many factors that don't directly affect PTC Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PTC Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if PTC Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PTC Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.